Effect of Anlotinib in the Adjuvant Treatment of Non-small Cell Lung Cancer and Its Effect on TGF-β1 and MMP2 Levels

ZHANG Yan; YAN Yuxiao

doi:10.14033/j.cnki.cfmr.2024.30.013

Abstract：Objective:To investigate the effect of Antirotinib in the adjuvant treatment of non-small cell lung cancer (NSCLC) and its effect on the levels of transforming growth factor-β1 (TGF-β1) and matrix metalloproteinase 2 (MMP2). Method:According to different treatments,80 patients with NSCLC in the hospital from March 2020 to November 2023 were divided into group A (n=40) and group C (n=40). Group A was treated with Pemetrexed and Cisplatin,while group C was treated with Anlotinib. The clinical efficacy,tumor markers,TGF-β1,MMP2 levels,quality of life and adverse reactions were compared between the two groups. Result:The therapeutic effective rate of group C was higher than that of group A (P<0.05). After treatment,cytokeratin 19 fragment antigen (CYFRA21-1),carbohydrate antigen 125 (CA125) and carcino-embryonic antigen (CEA) in group C were lower than those in group A (P<0.05). After treatment,the levels of TGF-β1 and MMP2 in group C were lower than those in group A (P<0.05),the lung cancer Quality of Life of Functional Assessment Cancer Therapy-Lung (FACT-L) and KPS scores in group C were higher than those in group A (P<0.05). There was no significant difference in the comparison of reactions between the two groups (P>0.05). Conclusion:Anlotinib has a significant effect in the adjuvant treatment of NSCLC,which can reduce the tumor markers,TGF-β1 and MMP2 levels of patients,improve the quality of life and have good safety.